https://www.selleckchem.com/products/ho-3867.html
It is known that lung function decline in Alpha-1 Antitrypsin Deficiency (AATD) varies. Those with a rapid decline are at highest risk of poorer outcomes but may benefit most from targeted treatments including augmentation therapy. Current evidence suggests rapid decliners can be identified after 3 years of serial follow-up. It would be advantageous to identify these patients over a shorter time period, especially in mild disease. Post-bronchodilator spirometry was performed every 6 months for a total of 18 months (4 measurements) by Pi
Like
Comment
Share
